The Importance of Intervention in Chronic Phase Myelofibrosis
Srdan Verstovsek, MD, PhD, professor in the Department of Leukemia and director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the importance of intervention in chronic phase myelofibrosis.<br />
Srdan Verstovsek, MD, PhD, professor in the Department of Leukemia and director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the importance of intervention in chronic phase myelofibrosis.
Although myelofibrosis is considered a chronic disease, it does not stay chronic forever, says Verstovsek. The average survival for patients with myelofibrosis is 5 to 7 years, but giving ruxolitinib (Jakafi) in the chronic phase for some patients can prolong life. Patients with myelofibrosis are at risk of their disease transforming to acute myeloid leukemia (AML), which has a worse prognosis and limited therapeutic options. Verstovsek says that patients must be monitored for disease transformation carefully, as AML does not develop overnight.
Tucatinib Plus T-DM1 Improves PFS in Previously Treated HER2+ Metastatic Breast Cancer
December 6th 2023The introduction of tucatinib to ado-trastuzumab emtansine significantly improved progression-free survival vs placebo plus T-DM1 in patients with previously treated HER2-positive metastatic breast cancer.
Read More
Pembrolizumab/Olaparib Did Not Improve Survival in Locally Advanced or Metastatic TNBC
December 6th 2023Maintenance pembrolizumab plus olaparib did not improve progression-free or overall survival in patients with locally recurrent inoperable or metastatic triple-negative breast cancer.
Read More
Neoadjuvant Chemo/Pembro Betters pCR in Key ER+ Breast Cancer Subgroups
December 6th 2023Adding pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab with endocrine therapy demonstrated improvements pathologic complete responses in key subsets of patients with early-stage, high-risk, estrogen receptor–positive/HER2-negative breast cancer.
Read More
ctDNA May Identify Risk of Recurrence in Early Breast Cancer Subgroup
December 6th 2023Patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer given abemaciclib for 2 years in addition to endocrine therapy demonstrated an association between ctDNA positivity and disease recurrence.
Read More
Capivasertib Shows Superior PROs Vs Placebo in HR+, HER2- Breast Cancer
December 6th 2023Patient-reported outcomes of the CAPItello-291 study of capivasertib plus fulvestrant showed a positive benefit-risk profile for the combination in patients with HR-positive, HER2-negative advanced breast cancer.
Read More
